tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Kontafarma China Holdings Announces New R&D Complex Construction in Beijing

Story Highlights
Kontafarma China Holdings Announces New R&D Complex Construction in Beijing

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Kontafarma China Holdings Ltd ( (HK:1312) ) has provided an announcement.

Kontafarma China Holdings Ltd, through its subsidiary Tongfang Pharmaceutical, has entered into a construction contract with Beijing Qingkong for the development of a new R&D complex in Beijing, valued at approximately RMB33.67 million. This transaction is considered both discloseable and connected, requiring independent shareholder approval due to its association with the company’s controlling shareholder, Shenzhen Waranty. The project is expected to strengthen Kontafarma’s research capabilities, potentially impacting its market position positively.

More about Kontafarma China Holdings Ltd

Kontafarma China Holdings Ltd operates in the pharmaceutical industry, primarily focusing on research and development. The company is involved in the construction of R&D complexes to enhance its capabilities in the pharmaceutical sector.

Average Trading Volume: 1,142,666

Technical Sentiment Signal: Sell

Current Market Cap: HK$172.9M

See more insights into 1312 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1